Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 19:11:1252.
doi: 10.3389/fphar.2020.01252. eCollection 2020.

Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study

Rongrong Wang  1 , Weili Wang  2 , Kuifen Ma  1 , Xin Duan  2 , Fangfang Wang  3 , Mingzhu Huang  1 , Wei Zhang  2 , Tingbo Liang  2
Affiliations

Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study

Rongrong Wang et al. Front Pharmacol. .

Abstract

Objective: High variabilities in tacrolimus (TAC) exposure are still problems that confuse physicians. TAC trough levels (TAC Cmin) fluctuated considerably after endoscopic retrograde cholangiopancreatography (ERCP) treatment in several liver transplant (LT) patients. We aimed to investigate the variation regularity of TAC Cmin post-ERCP and related factors.

Methods: This study was a retrospective, observational study conducted at the First Affiliated Hospital of Zhejiang University in China. From October 2017 to January 2019, 26 LT patients that received ERCP were included (73 TAC Cmin measures). The absolute difference and the variation extent in TAC Cmin pre- and post-ERCP were analyzed. Patients were divided into mild and obvious variation groups, and the differences were compared.

Results: The TAC Cmin in LT patients significantly increased in the first three days post-ERCP (p<0.05) and increased by more than 20% in 18 out of 26 (69.2%) patients. The mean extent of variation in TAC Cmin was 45.1% (95% confidence interval [CI]: 28.3-81.3%) and 31.4% (95% CI: 9.7-53.1%) on days 1 and 3 post-ERCP, respectively. The increasing TAC Cmin gradually returned to baseline within a week (p>0.05). The daily TAC dose and total bile acid (TBA) level were significantly higher (p<0.05) in patients with obvious variation in TAC Cmin. The differences in other demographics, clinical characteristics, variation in laboratory data, and serum amylase levels between the two groups were not significant.

Conclusion: The TAC Cmin significantly increased in LT patients during the first three days after ERCP, and the level returned to baseline within a week. The daily TAC dose and TBA levels may be related to this increase. Frequent drug concentration monitoring should be executed in the early phase post-ERCP, especially in patients with related factors.

Keywords: endoscopic retrograde cholangiopancreatography; liver transplant; related factors; tacrolimus; trough concentration.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flow diagram.
Figure 2
Figure 2
Variation of TAC Cmin pre- and post-ERCP. (A) Extent of variation in TAC Cmin pre- and post-ERCP (Standard TAC Cmin). Bars represent mean ± SD. (B) Absolute variation of TAC Cmin pre- and post-ERCP.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Astellas Pharma US Inc (2015). Tacrolimus (Prograf). Product Insert (Northbrook, IL: ).
    1. Barthet M., Desjeux A., Gasmi M., Bellon P., Hoi M. T., Salducci J., et al. (2002). Early refeeding after endoscopic biliary or pancreatic sphincterotomy: a randomized prospective study. Endoscopy 34 (7), 546–550. 10.1055/s-2002-33227 - DOI - PubMed
    1. Brunet M., van Gelder T., Asberg A., Haufroid V., Hesselink D. A., Langman L., et al. (2019). Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther. Drug Monit. 41 (3), 261–307. 10.1097/FTD.0000000000000640 - DOI - PubMed
    1. Campagne O., Mager D. E., Tornatore K. M. (2019). Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities? J. Clin. Pharmacol. 59 (3), 309–325. 10.1002/jcph.1325 - DOI - PMC - PubMed
    1. Charlton M., Levitsky J., Aqel B., O’Grady J., Hemibach J., Rinella M., et al. (2018). International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation 102 (5), 727–743. 10.1097/TP.0000000000002147 - DOI - PubMed

LinkOut - more resources